Protecting Innovation in the Life Sciences
​​​​​​Revere, Boston Common, MA
Date TBC 

We have taken the difficult decision to postpone the upcoming Life Sciences Patent Network - North America - Spring event. Many of our attendees are experiencing travel restrictions due to COVID-19 and the safety of all concerned is our top priority. 


We are currently working with the venue and our current sponsors and delegates to secure a new date and will be in touch as soon as possible with an update. 

Join us for the 4th annual LSPN North America - Spring conference!

In response to the numerous requests for an even bigger conference programme, we are delighted to announce that LSPN Spring 2020 will now take place over two days, enabling even more networking opportunities and a packed programme of presentations and panel discussions. You wanted more round table discussion time, so this year’s conference enables you to join four 45 minute discussion groups of your choosing.

You told us that you wanted a networking dinner. So - brand new for 2020, we present you with the LSPN Gala Dinner!

Taking place on the evening of day one of the conference, the gala dinner and drinks reception is a great opportunity to relax after the conference, in the company of your fellow delegates, speakers and sponsors. Places at the dinner are limited, so we urge you to sign up to attend the Gala Dinner when you book your delegate place so as not to miss out.

Over 50% of LSPN network attendees are in-house counsel

Brought to you by Life Sciences Intellectual Property Review, the 4th Annual Life-Sciences Patent Network NORTH AMERICA is the first of the 2020 patent conference series, which presents an unrivalled gathering of in-house patent counsel from established and fledgling pharmaceutical and biotechnology companies coming together to listen to updates on patent prosecution and enforceability from global jurisdictions, meet in informal discussion groups, and source specialist IP attorneys who can assist them with their IP portfolio strategies over the coming year.
The conference, taking place once again in Boston, MA provides delegates with an invaluable opportunity to gain insight into the sector issues of critical current importance; listen to best-in-class case studies; keep abreast of the likely forward impact of key judgements and political jolts; and network with global patent peers.
Following on from the hugely successful LSPN conferences in London and Singapore, the Boston conference takes a broad global view of the patent protection landscape and then delves deeper into the topics of specific current interest. Extended round table discussion groups enable a couple of hours to be spent in small groups, sharing views on a range of topics of the delegates’ choosing. For fledgling bio-pharma manufacturers, the conference features a hugely popular open clinic to enable in-house counsel to quiz specialist private patent attorneys from around the globe on their own specific pressing patent issues.   

As well as conference presentations and the in-depth panel discussion along with audience Q&A, sessions and the discussion groups, a great deal of networking time is set aside throughout the day for networking opportunities, starting with welcome coffee, continuing through networking coffee breaks and a three course lunch – and culminating in informal drinks and canapés for all speakers, sponsors and delegates.  

In-House Counsel 2019 Attendees Included:

  • Vice President, General Counsel & Corporate Secretary, Pieris Pharmaceuticals
  • Senior Patent Counsel, Pfizer
  • Counsel, Merck Sharp & Dohme
  • Chief Scientific Officer, CareDx
  • Chief Intellectual Property Counsel, Memorial Sloan Kettering Cancer Center
  • Patent Counsel, Boston Scientific
  • VP Intellectual Property & Research, RedHill Biopharma
  • Associate Director & Senior Counsel, IP & EHS, Boehringer Ingelheim Pharmaceuticals
  • Director, Intellectual Property, Alkermes
  • Vice President Licensing, IP & Legal Affairs, Pieris Pharmaceuticals
  • Principal Counsel, Sanofi
  • Associate Director & Corporate Counsel - Intellectual Property, Boehringer Ingelheim Pharmaceuticals Inc
  • Vice President, Intellectual Property, Scholar Rock
  • Chief IP Counsel, Biogen
  • Senior Licensing Associate, University Of Central Florida
  • Legal Counsel, IP and Contracts, VBI Vaccines Inc.
  • Executive Director, IP Counsel, Bioverativ
  • Senior Patent Attorney, Takeda
  • Vice President, Intellectual Property, Alkermes
  • Patent Agent, Alnylam Pharmaceuticals
  • Senior Content Manager, Novartis
  • VP Intellectual Property & Research, RedHill Biopharma
  • Senior Corporate Counsel, Sanofi
  • Director of Intellectual Property, Jounce Therapeutics
  • Partner, Venable Fitzpatrick
  • Senior Patent Counsel, Global IP, Sanofi
  • Director, Intellectual Property, Alkermes
  • Senior European Patent Attorney and US Patent Agent, Novartis
  • Patent Attorney, Novartis
  • Senior Patent Counsel, Takeda
  • VP, Patent Head Oncology & IP Site Head, Novartis 
  • Senior Counsel, Merck & Co
  • Director of Technology Transfer Policy, Harvard University, Office of Technology Development
  • General Counsel, Pharming Healthcare, Inc.
  • Senior Counsel, Sanofi
  • VP Corporate Affairs, Turnstone Biologics
  • Senior Manager, Takeda
  • Global Franchise Head, R&D Patents, Novartis
  • Principal, Biospark IP
  • Attorney, Alexion Pharmaceuticals, Inc.
  • Senior Counsel, Amgen
  • Senior Patent Agent, Pure Tech Health
  • VP, IP, Dicerna Pharmaceuticals , Inc
  • Senior Patent Counsel, Takeda
  • Product Sales Manager, Clarivate Analytics
  • Patent Agent, Pieris Pharmaceuticals
  • Director in Policy, Research, and Membership, PhRMA
  • Global Counsel - Intellectual Property, Mylan Inc
  • Chief IP Counsel, Memorial Sloan Kettering Cancer Center
  • Senior Corporate Counsel, Pfizer Inc
  • Patent Counsel, Boston Scientific Corporation
  • Principal Counsel, Head of Biologic Patents US, Sanofi
  • Sr. Director, IP, Vertex Pharmaceuticals
  • Principal, Biospark IP
  • Attorney, Alexion Pharmaceuticals, Inc.
  •  Global Franchise Head, R&D Patents, Novartis
  •  Senior Manager, Takeda
  • VP Corporate Affairs, Turnstone Biologics
  • Senior Counsel, Sanofi
  • Director of Technology Transfer Policy,Harvard University, Office of Technology Development 

Why Attend LSPN Spring?

"There was a good ratio of in-house counsels and patent professionals attending the conference. The roundtable sessions were particularly engaging"

(C W  Yeng, Head IP Strategy, Taylor Vinters Singapore)

2020 Speakers Include:

In partnership with: